ArticleFrontiers in psychiatry2022
The effect of antipsychotics on glutamate levels in the anterior cingulate cortex and clinical response: A
Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 12 citations in OpenAlex.
- Effects of antipsychotics on human cognitive function: causal evidence from healthy volunteers following sustained D2/D3 antagonism, D2/D3 partial agonism and placebo.Molecular psychiatry · 2025Trial
- Higher-order functional brain networks and anterior cingulate glutamate + glutamine (Glx) in antipsychotic-naïve first episode psychosis patients.Translational psychiatry · 2024Trial
- Effect of age, sex, and BMI on serum olanzapine levels and their correlation with metabolic parameters and serum pro-inflammatory cytokine levels in schizophrenia patients.BMC psychiatry · 2026Article
- Why Is Clozapine Uniquely Effective in Treatment-Resistant Schizophrenia? A Review and Proposal.Biological psychiatry · 2026Review
- Investigating the disturbance in cortical glutamate and GABA function in psychosis and its origins and consequences.Molecular psychiatry · 2026Article
- What is Minimally Adequate Treatment of Psychosis and Should Duration of Inadequate Treatment be a Clinical and Research Target? A Perspective and State-of-the-Art Review.Schizophrenia bulletin · 2026Review
- Elevated glutamine but not glutamate is associated with clozapine eligibility in an early psychosis sample.Frontiers in psychiatry · 2026Article
- Effect of olanzapine on changes in serum complement factors levels in patients with first-episode schizophrenia.BMC psychiatry · 2025Article
- Changes in glutamate levels in anterior cingulate cortex following 16 weeks of antipsychotic treatment in antipsychotic-naïve first-episode psychosis patients.Psychological medicine · 2025Article
- Peripheral blood complement factors C2 and C3 as biomarkers of clinical efficacy in patients with first-episode schizophrenia after aripiprazole treatment.BMC psychiatry · 2024Article
- Exploring causal mechanisms of psychosis risk.Neuroscience and biobehavioral reviews · 2024Review
- The association between peripheral inflammation, brain glutamate and antipsychotic response in Schizophrenia: Data from the STRATA collaboration.Brain, behavior, and immunity · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
Abstract
Introduction: Glutamatergic dysfunction is implicated in the pathophysiology of schizophrenia. It is unclear whether glutamatergic dysfunction predicts response to treatment or if antipsychotic treatment influences glutamate levels. We investigated the effect of antipsychotic treatment on glutamatergic levels in the anterior cingulate cortex (ACC), and whether there is a relationship between baseline glutamatergic levels and clinical response after antipsychotic treatment in people with first episode psychosis (FEP). Materials and methods: The sample comprised 25 FEP patients; 22 completed magnetic resonance spectroscopy scans at both timepoints. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS). Results: There was no significant change in glutamate [baseline 13.23 ± 2.33; follow-up 13.89 ± 1.74; t(21) = -1.158, Conclusion: These findings indicate that treatment response is unlikely to be associated with baseline glutamatergic metabolites prior to antipsychotic treatment, and there is no major effect of antipsychotic treatment on glutamatergic metabolites in the ACC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.